A Safety Study of Brentuximab Vedotin in Participants With HIV - Trial NCT05244473
Access comprehensive clinical trial information for NCT05244473 through Pure Global AI's free database. This Phase 1 trial is sponsored by Seagen Inc. and is currently Withdrawn. The study focuses on Human Immunodeficiency Virus. Target enrollment is 0 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Seagen Inc.
Timeline & Enrollment
Phase 1
Dec 31, 2022
May 31, 2024
Primary Outcome
Number of participants with adverse events (AEs),Number of participants with laboratory abnormalities,Number of participants with dose-limiting toxicities (DLTs) by dose level
Summary
This study will test brentuximab vedotin to see if it is safe for people with human
 immunodeficiency virus (HIV) who have low CD4+ and have received antiretroviral therapy (ART)
 treatment. It will also see if brentuximab vedotin raises CD4+ counts. It will study the side
 effects of this drug as well. A side effect is anything a drug does to the body besides
 treating the disease.
 
 In this study participants will be assigned randomly to a group. Participants will get either
 brentuximab vedotin or placebo. A placebo looks like the drug but does not contain any
 medicine in it. All participants will keep getting ART during the study.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05244473
Non-Device Trial